SCHEMBL4500026

SCHEMBL4500026

CC(C)(C)c1ccc(COc2cccc(-n3cnc4cc(C(=O)NCc5cccnc5)ccc43)c2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.56
RECQL P46063 1/20 0.56
HTT P42858 4/20 0.56
ALDH1A1 P00352 3/20 0.56
MAPT P10636 2/20 0.56
SMN1; SMN2 Q16637 3/20 0.54
MAPK1 P28482 3/20 0.54
NPC1 O15118 1/20 0.54
RAB9A P51151 1/20 0.54
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
NAMPT P43490 1/20 0.49
GPR132 Q9UNW8 1/20 0.49
TP53 P04637 2/20 0.48
TDP1 Q9NUW8 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
GFER P55789 1/20 0.47
HPGD P15428 2/20 0.47
GAA P10253 1/20 0.47
ALOX12 P18054 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1383844 0.92 LMNA (0.54) LMNARECQLHTTALDH1A1MAPT
SCHEMBL1382294 0.91 LMNA (0.59) LMNARECQLHTTMAPTSMN1; SMN2
SCHEMBL1381717 0.91 LMNA (0.55) LMNARECQLHTTALDH1A1SMN1; SMN2
SCHEMBL4510328 0.91 LMNA (0.58) LMNARECQLHTTALDH1A1MAPT
SCHEMBL1378061 0.91 LMNA (0.56) LMNARECQLHTTALDH1A1SMN1; SMN2
SCHEMBL4506055 0.90 LMNA (0.54) LMNARECQLHTTALDH1A1SMN1; SMN2
SCHEMBL1379465 0.88 LMNA (0.53) LMNARECQLHTTALDH1A1SMN1; SMN2
SCHEMBL1381545 0.88 LMNA (0.52) LMNARECQLHTTALDH1A1SMN1; SMN2
SCHEMBL1378687 0.87 LMNA (0.51) LMNARECQLHTTALDH1A1MAPT
SCHEMBL1380443 0.87 L3MBTL1 (0.59) LMNARECQLHTTALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060189629-A1 N-substituted benzimidazolyl c-Kit inhibitors OSI PHARMACEUTICALS, INC. 2006-08-24 US claimed
US-7521448-B2 N-substituted benzimidazolyl c-Kit inhibitors OSI PHARMACEUTICALS, INC. (US) 2009-04-21 US disclosed
US-20060189629-A1 N-substituted benzimidazolyl c-Kit inhibitors OSI PHARMACEUTICALS, INC. 2006-08-24 US disclosed
EP-1664021-A1 N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS OSI Pharmaceuticals, Inc. (US) 2006-06-07 EP disclosed
WO-2005021531-A1 N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS OSI PHARMACEUTICALS, INC. (US) 2005-03-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060189629-A1 N-substituted benzimidazolyl c-Kit inhibitors KIT, CHUK, TNNI3K LMNA 2408/4885RECQL 2054/4885HTT 4544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.